

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Psoriasis	IL-22; pim-1 (PIM1)	<p>Mouse studies suggest inhibiting IL-22 or PIM1 could help treat psoriasis. In a xenotransplant mouse model of severe human psoriasis, injection of an anti-IL-22 mAb reduced psoriasis symptoms as effectively as an anti-tumor necrosis factor (TNF) mAb. Gene expression network analysis of IL-22-injected skin, anti-IL-22 mAb-injected skin and the xenotransplant mouse model identified a core set of 32 differentially expressed genes, including <i>PIM1</i>. In a chemically induced mouse model of psoriasis, knockout or topical pharmacological inhibition of Pim1 blocked skin inflammation. Next steps could include testing the topical application of small molecule PIM1 inhibitors in patients with psoriasis.</p> <p>Generon (Shanghai) Corp. Ltd. has a recombinant protein containing a human IL-22 dimer, F-652, in Phase I trials to treat inflammation.</p> <p>Selvita S.A. has SEL24, a PIM1 kinase inhibitor, in preclinical development for cancer.</p> <p>SciBX 7(11); doi:10.1038/scibx.2014.307 Published online March 20, 2014</p>	Patent and licensing status unavailable	<p>Perera, G.K. <i>et al. Sci. Transl. Med.</i>; published online Feb. 12, 2014; doi:10.1126/scitranslmed.3007217 Contact: Frank O. Nestle, King's College London, London, U.K. e-mail: frank.nestle@kcl.ac.uk</p>